Actively Recruiting
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
Led by Beth Israel Deaconess Medical Center · Updated on 2026-04-02
1126
Participants Needed
1
Research Sites
302 weeks
Total Duration
On this page
Sponsors
B
Beth Israel Deaconess Medical Center
Lead Sponsor
B
Brigham and Women's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Infertility affects more than 6 million women the United States and is a major life event that results in a wide range of socio-cultural, emotional, physical and financial problems. The most successful treatment for infertility, in-vitro fertilization (IVF), fertilizes a woman's eggs with her partner's sperm in a culture dish and transfers the resulting embryos into the uterus. Most of the time, prior to being transferred, embryos are grown in the dish for 5-7 days after which some of them reach an advanced stage (blastocyst stage). This has several advantages such as a lower chance of a multiple pregnancies (twins, triplets etc.) after transfer and fewer transfer procedures. However, it is possible that embryos would survive better if transferred into the uterus at the 8-cell stage after growing them for only 3 days. Thus, when patients only have a small number of embryos they and their physicians face the difficult choice when to transfer because there are currently no studies available to guide this decision. This randomized controlled trial is comparing pregnancy outcomes and patient satisfaction of poor prognosis patients with 5 or fewer embryos undergoing either transfer of an advanced (blastocyst) or an 8-cell embryo. This study will provide the data for the development of guidelines for IVF providers to make evidence-based decisions when to transfer embryos in poor prognosis IVF patients, reduce patients' anxiety regarding cycle cancellation and improve patient counseling, which will increase patients' ability to participate in the development of their treatment plan.
CONDITIONS
Official Title
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Undergoing autologous IVF cycle
- Having 5 or fewer zygotes on day 1 of embryo development
- Receiving fresh embryo transfer
You will not qualify if you...
- Planned preimplantation genetic testing (PGT) of all embryos
- More than 2 previous IVF cycles
- History of recurrent pregnancy loss (3 or more losses)
- Body mass index (BMI) greater than 40
- Presence of uterine factor infertility
- Planned use of a gestational carrier
- Endometrial lining thinner than 6mm on the day of trigger
- Use of Lupron-only trigger or elevated progesterone (1.5 ng/ml or higher) in the fresh cycle
- Fertilization delayed more than 18 hours
- Use of rescue intracytoplasmic sperm injection after failed fertilization
- Use of non-ejaculated sperm (testicular sperm extraction)
- Number of embryos transferred outside American Society of Reproductive Medicine guidelines
- Cycle converted to all embryos being frozen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Boston IVF
Boston, Massachusetts, United States, 02451
Actively Recruiting
Research Team
B
Beatrice Duvert
CONTACT
W
Werner Neuhausser, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here